Exchange
TSE
Every company in the roster listed on TSE.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
16 of 16 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Daiichi Sankyo4568 · TSE | 12 assets: 3 approved, 5 Ph 3, 3 Ph 2, 1 Ph 1 | MirogabalinPhase 3 · Diabetic Peripheral Neuropathic PainReliable signal | 20 Oct 2026DS-3939a · Phase 1/2 |
 Otsuka Holdings4578 · TSE | 12 assets: 8 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1 | OPC-61815Phase 3 · Heart FailurePartial signal | 20 Oct 2026Ulotaront · Phase 3 |
 Eisai4523 · TSE | 9 assets: 5 approved, 3 Ph 3, 1 Ph 2 | LemborexantPhase 3 · Alzheimer's DiseasePartial signal | 3 Dec 2026Lecanemab · Phase 2 |
 Sumitomo Pharma4506 · TSE | 8 assets: 3 approved, 2 Ph 3, 2 Ph 2, 1 Ph 1 | Droxidopa (Northera)Phase 3 · Parkinson's DiseasePartial signal | 20 Oct 2026Ulotaront · Phase 3 |
 Astellas Pharma4503 · TSE | 7 assets: 2 approved, 4 Ph 3, 1 Ph 1 | RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal | 31 Oct 2026Setidegrasib · Phase 1 |
 Kyowa Kirin4151 · TSE | 6 assets: 2 approved, 1 Ph 3, 3 Ph 1 | RTA 402Phase 3 · Type 2 DiabetesReliable signal | Dec 2027KK3910 · Phase 1 |
 Ono Pharmaceutical4528 · TSE | 5 assets: 3 Ph 2, 2 Ph 1 | ONO-1110Phase 2 · Major Depressive DisorderPartial signal | 31 Dec 2026ONO-2020 · Phase 2 |
 Kissei Pharmaceutical4547 · TSE | 4 assets: 2 Ph 3, 2 Ph 2 | JR-131Phase 3 · Chronic Kidney DiseasePartial signal | None on record |
 Asahi Kasei Corporation3407 · TSE | 2 assets: 1 approved, 1 Ph 2 | GKT137831Phase 2 · Primary Biliary Cholangitis | Mar 2027Budesonide (targeted-release) · Approved |
 Chugai Pharma4519 · TSE | 2 assets: 1 approved, 1 Ph 1 | AQUA07Phase 1 · Non-Small Cell Lung Cancer | 31 Aug 2030AQUA07 · Phase 1 |
 Shionogi4507 · TSE | 2 assets: 2 Ph 3 | PravafenixPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 AnGes4563 · TSE | 1 asset: 1 Ph 3 | Beperminogene perplasmid (HGF plasmid)Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | None on record |
 BrightPath Biotherapeutics Co., Ltd.4594 · TSE | 1 asset: 1 Ph 1 | BP2202Phase 1 · Multiple Myeloma | 31 Dec 2027BP2202 · Phase 1 |
 Heartseed219A · TSE | 1 asset: 1 Ph 2 | HS-001Phase 1/2 · Heart Failure | None on record |
 Kaken Pharmaceutical4521 · TSE | 1 asset: 1 Ph 3 | EnvudeucitinibPhase 3 · PsoriasisReliable signal | 1 Dec 2027Envudeucitinib · Phase 2 |
 Rohto Pharmaceutical4527 · TSE | 1 asset: 1 Ph 2 | ADR-002KPhase 2 · Heart Failure | 30 Sep 2028ADR-002K · Phase 2 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).